WIRB-Copernicus Group (WCG), a clinical services organization, said that its clinical services division has acquired Waife & Associates (W&A), a provider of management consulting services for biopharma clinical research clients.

Financial terms of the acquisition were not disclosed by the parties.

Waife & Associates is engaged in making clinical development more efficient and productive by driving improvements in organization, process, and technology.

The company is claimed to have catered to 200 plus clients globally, including biopharma research sponsors, clinical research organizations (CROs), technology vendors and investors.

The services of Waife & Associates include clinical operations process improvement, implementation management, information technology strategy, service/product vendor selection and oversight, virtual executive management, and pharmacovigilance process improvement.

Donald A. Deieso – Executive Chairman and CEO of WIRB-Copernicus Group said: “With this acquisition, WCG has taken another important step toward its goal of providing comprehensive transformational services to those conducting clinical trials.

“We have long recognized that research sites and sponsors universally need assistance in improving the speed and efficacy of their operational processes. We are excited to add W&A’s unique expertise, perspective and skills to accelerate improvement in research enterprises. We look forward to expanding the breadth of their market impact and enabling them to draw on WCG’s rich knowledgebase of data and resources to inform and enhance the operations of those who sponsor and conduct life-saving clinical research.”

Waife & Associates offers analysis and executes recommendations to address a variety of organizational and technology questions which emerge throughout the clinical development process.

The company is said to have worked across all clinical research technology domains and organizational issues like structure, outsourcing, staffing, process evaluation, vendor management, and market positioning for service providers.

Ronald S. Waife – Founder of Waife & Associates said: “We are greatly pleased to join WCG, which is demonstrating a true commitment to innovation and transformation in drug development.

“The possibilities this offers us to expand our contributions, and create new opportunities for new solutions, is very exciting to us.”

Waife & Associates will continue to function independently and retain its headquarters located in Needham, Massachusetts. The company will get access to capital, expertise and corporate operational support from WIRB-Copernicus Group.

Related posts

• Celgene, Acceleron bag Reblozyl FDA approval for anemia in beta thalassemia (0)
• MicroMedicine to introduce new white blood cell isolation technology at SITC annual conference (0)
• Biodesix acquires Oncimmune’s laboratory and IPN malignancy test in US (0)
• Pandion bags $795m deal with Astellas for pancreas-targeted immunomodulators (0)
• Dicerna, Roche strike $1.67bn deal for hepatitis B virus therapies (0)
• Cellectis begins MELANI-01 clinical trial for UCARTCS1 in multiple myeloma (0)
• Mirum gets FDA breakthrough therapy status for maralixibat for Alagille syndrome (0)
• Arena begins ADVISE clinical trial for etrasimod in atopic dermatitis (0)
• LIPAC Oncology takes NMIBC treatment TBC-1002 into phase 2 A trial (0)
• Talaris initiates FREEDOM-1 clinical trial for FCR001 in LDKT recipients (0)